Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Public ClinicalTrials.gov record NCT04596150. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination With Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
Study identification
- NCT ID
- NCT04596150
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 125 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2020 (Actual)
- Primary completion
- Jun 2, 2023 (Actual)
- Completion
- Jun 2, 2023 (Actual)
- Last update posted
- Jan 23, 2024
2020 – 2023
United States locations
- U.S. sites
- 27
- U.S. states
- 20
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center | La Jolla | California | 92093 | — |
| Los Angeles Hematology Oncology Medical | Los Angeles | California | 90017 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| UCLA David Geffen | Santa Monica | California | 90404 | — |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | — |
| FCS - South | Fort Myers | Florida | 33901 | — |
| Baptist Medical Center | Jacksonville | Florida | 32207 | — |
| Hematology Oncology Assoc of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| FCS - North | St. Petersburg | Florida | 33705 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Hematology Oncology Clinic | Baton Rouge | Louisiana | 78809 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| MGH | Boston | Massachusetts | 02114 | — |
| DRCI | Boston | Massachusetts | 02215 | — |
| Allina Health System | Minneapolis | Minnesota | 55407 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| UPMC Magee-Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| MUSC | Charleston | South Carolina | 29425 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| UT Health East Texas HOPE Cancer Center | Tyler | Texas | 75701 | — |
| Huntsman Cancer Institute Research | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Summit Cancer Centers | Spokane | Washington | 99208 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04596150, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04596150 live on ClinicalTrials.gov.